Allergan (AGN) Given a $245.00 Price Target at Wells Fargo & Co

Wells Fargo & Co set a $245.00 price target on Allergan (NYSE:AGN) in a report released on Friday. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. Piper Jaffray Companies set a $227.00 price objective on shares of Allergan and gave the stock a hold rating in a research report on Friday, October 13th. Royal Bank of Canada restated an outperform rating and issued a $250.00 price objective (down from $277.00) on shares of Allergan in a research report on Thursday, October 19th. They noted that the move was a valuation call. Leerink Swann restated an outperform rating and issued a $237.00 price objective on shares of Allergan in a research report on Monday, November 27th. UBS Group restated a buy rating and issued a $275.00 price objective on shares of Allergan in a research report on Tuesday, September 26th. Finally, Vetr cut shares of Allergan from a strong-buy rating to a buy rating and set a $187.73 price objective on the stock. in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. Allergan has an average rating of Hold and an average price target of $230.99.

Allergan (NYSE AGN) traded down $3.59 during mid-day trading on Friday, hitting $168.70. 429,415 shares of the company traded hands, compared to its average volume of 2,920,000. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The company has a market capitalization of $57,300.00, a PE ratio of -7.47, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. Allergan has a one year low of $160.07 and a one year high of $256.80.

Allergan (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. Allergan’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.32 earnings per share. equities analysts anticipate that Allergan will post 16.27 earnings per share for the current fiscal year.

Allergan declared that its Board of Directors has approved a share repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, November 17th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.66%. The ex-dividend date was Thursday, November 16th. Allergan’s payout ratio is currently -12.39%.

In other news, insider William Meury sold 11,807 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Chris W. Bodine bought 3,030 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was purchased at an average price of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. Insiders have acquired 17,630 shares of company stock worth $2,890,057 over the last quarter. Company insiders own 0.36% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Peloton Wealth Strategists grew its holdings in shares of Allergan by 37.1% in the third quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock worth $2,149,000 after purchasing an additional 2,835 shares during the last quarter. Sumitomo Life Insurance Co. grew its holdings in shares of Allergan by 39.0% in the third quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock worth $3,099,000 after purchasing an additional 4,244 shares during the last quarter. Colony Group LLC lifted its stake in Allergan by 9.9% in the second quarter. Colony Group LLC now owns 39,802 shares of the company’s stock worth $9,675,000 after acquiring an additional 3,577 shares during the period. Clear Harbor Asset Management LLC lifted its stake in Allergan by 67.7% in the third quarter. Clear Harbor Asset Management LLC now owns 5,039 shares of the company’s stock worth $1,033,000 after acquiring an additional 2,035 shares during the period. Finally, Alta Capital Management LLC lifted its stake in Allergan by 1.4% in the third quarter. Alta Capital Management LLC now owns 161,377 shares of the company’s stock worth $33,074,000 after acquiring an additional 2,151 shares during the period. Hedge funds and other institutional investors own 81.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/08/allergan-agn-given-a-245-00-price-target-at-wells-fargo-co.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit